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ABSTRACT  58 
Background  59 
There is no effective intravesical second-line therapy for non-muscle invasive 60 
bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. 61 
Objective 62 
To compare disease-free survival time (DFS) between radiofrequency-induced 63 
thermo-chemotherapy effect (RITE) and institutional standard second-line therapy 64 
(control) in NMIBC patients with recurrence following induction/ maintenance BCG.  65 
Design, settings, and participants 66 
Open-label, phase III randomised controlled trial accrued across 14 centres between 67 
May 2010 and July 2013 [HYMN (ClinicalTrials.gov: NCT01094964)].  68 
Interventions 69 
Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42±2°C) 70 
or control following stratification for CIS status (present/absent), therapy history 71 
(failure of previous induction/ maintenance BCG) and treatment centre. 72 
Outcome measurements and statistical analysis  73 
Primary outcome measures were DFS and complete response (CR) at three months 74 
for the CIS at randomisation subgroup. Analysis was by intention-to-treat.  75 
Results and limitations 76 
A total of 104 patients were randomised (48 RITE: 56 control). Median follow-up for 77 
the 31 patients without a DFS event was 36 months. There was no significant 78 
difference in DFS between treatment arms (HR 1.33, [95% CI 0.84-2.10], p=0.23) or 79 
in three-month CR rate in CIS patients (n=71; RITE: 30% vs control: 47%, p=0.15). 80 
There was no significant difference in DFS between treatment arms in non-CIS 81 
patients (n=33; RITE: 53% vs control: 24% at 24 months, HR 0.50 [0.22-1.17], 82 
p=0.11). DFS was significantly lower in RITE compared to control in CIS with/without 83 
papillary patients (n=71; HR 2.06 [1.17-3.62], p=0.01; treatment-subgroup interaction 84 
p=0.007. Disease progression was observed in 4 patients in each treatment arm. 85 
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Adverse events and health-related quality-of-life between treatment arms were 86 
comparable.  87 
Conclusion  88 
DFS was similar between RITE and control. RITE may be a second line therapy for 89 
non-CIS recurrence following BCG failure although confirmatory trials are needed. 90 
RITE patients with CIS with/without papillary had lower DFS compared to control. 91 
HYMN highlights the importance of the control arm when evaluating novel therapies. 92 
 93 
Patient summary 94 
This study did not show a difference in bladder cancer outcomes between 95 
microwave heated chemotherapy and standard of care treatment. Papillary bladder 96 
lesions may benefit from microwave heated chemotherapy treatment, but more 97 
research is needed. Both treatments are similarly well tolerated.  98 
 99 
Key words: bladder cancer, BCG failure, chemotherapy, device assisted therapy, 100 
hyperthermia, mitomycin-C, radiofrequency, randomised controlled trial, 101 
thermotherapy 102 
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1. INTRODUCTION 108 
Non-muscle invasive bladder cancer (NMIBC) represents 75% of bladder cancer and 109 
adjuvant intravesical bacillus Calmette Guérin (BCG) is recommended for high risk 110 
NMIBC following transurethral resection (TUR) of papillary urothelial carcinoma or as 111 
ablative therapy for carcinoma in situ (CIS). 112 
Despite maintenance BCG therapy, 55% of NMIBC patients develop recurrence and 113 
20% progress to muscle invasive bladder cancer (MIBC) within 5 years [1]. 114 
Guidelines advocate early cystectomy or re-challenge with BCG following BCG 115 
failure [2-4]. Although early cystectomy is the standard of care, it remains a morbid 116 
procedure with a 90-day mortality of between 3.0-6.9% [5, 6]. Guidelines 117 
recommending re-challenging with BCG accept its limited efficacy and there is 118 
insufficient evidence to recommend the use of other intravesical agents [4, 7]. 119 
Radical  radiotherapy is not effective for NMIBC [8]. 120 
Radiofrequency-induced thermo-chemotherapy effect (RITE) is a promising therapy 121 
for NMIBC. RITE delivers hyperthermia to the bladder wall potentiating 122 
chemotherapy cytotoxic effects and increases drug absorption by the formation of 123 
tunnelling microtubules [9, 10] . A recent randomised controlled trial (RCT) of  BCG 124 
naïve NMIBC report a significantly higher 24-month RFS in RITE compared to BCG 125 
treated patients (82% vs 65%, p=0.02) in per-protocol analysis (PPA) consistent with 126 
previous studies [11, 12].  127 
There has been no RCT comparing RITE to control in patients with recurrence of 128 
NMIBC following failure of induction/ maintenance BCG. We report the results of 129 
HYMN, a phase III RCT comparing RITE to control defined as a second course of 130 
BCG or institutional standard in patients with NMIBC recurrence following induction 131 
or maintenance BCG (ClinicalTrials.gov: NCT01094964, CRUK/09/012).                                                                                                                                           132 
                    133 
 134 
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 136 
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2. METHODS 138 
2.1 Trial design 139 
HYMN is an open-label, two-arm, phase III RCT performed in accordance with the 140 
Declaration of Helsinki. Fourteen institutions throughout the UK participated in the 141 
trial (Supplementary Table 1). Appropriate ethical review board approved the trial 142 
protocol (v4.0) at all recruiting sites (IRAS 10306).   143 
2.2 Patients 144 
Patients with recurrence of intermediate or high risk NMIBC according to European 145 
Association of Urology (EAU) guidelines following induction/ maintenance BCG were 146 
eligible [2]. All patients had complete TUR of papillary lesions and in pT1 disease 147 
underwent re-resection to confirm the absence MIBC. Other inclusion criteria were 148 
age ≥18 years, WHO performance status ≤4 and patients unfit or unwilling to have 149 
radical cystectomy. All patients had imaging to exclude upper tract disease ≤12 150 
months. Haematological and biochemical blood tests were within normal limits.  151 
Key exclusion criteria included non-urothelial carcinoma, low grade NMIBC 152 
recurrence, treatment with intravesical chemotherapy ≤6 months (single post-TUR 153 
instillation allowed), prostatic urethra or upper tract disease, known mitomycin-C 154 
allergy, active/ intractable urinary tract infection, urethral stricture, small bladder 155 
capacity (<250 ml), significant urinary incontinence or history of pelvic radiotherapy.  156 
2.3 Randomisation and masking 157 
Patients were randomised (1:1 ratio) using a random treatment allocation sequence 158 
generated by the Cancer Research UK Clinical Trial Unit (CRCTU), University of 159 
Birmingham, which was concealed from participants and accessed by telephone 160 
using a central computerised randomisation service at CRCTU. Randomisation was 161 
stratified by CIS status (present/absent), therapy history (failure of previous 162 
induction/ maintenance BCG) and treatment centre. An independent Data Monitoring 163 
Committee (DMC) was appointed to oversee the safety and monitor the interim 164 
efficacy of treatment arms within the trial. 165 
2.4 Interventions  166 
Patients allocated to the experimental arm received six-weekly induction instillations 167 
of RITE using the Synergo® SB-TS 101 System [13, 14]. Treatment comprise of two 168 
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30-minute cycles, each with 20mg MMC (50 ml sterile water) at 42±2°C (40mg MMC 169 
in total) in accordance with the manufacturer’s guidance [15]. Dose reduction was 170 
not permitted. Patients disease-free three months after treatment commencement 171 
would proceed to maintenance RITE (one instillation of RITE every six weeks for 172 
year one and one instillation every eight weeks for year two).   173 
Patients allocated to the control arm received either six consecutive weekly BCG 174 
instillations (50ml normal saline) followed by maintenance therapy (three consecutive 175 
weekly instillations at three, six, 12, 18 and 24 months) or institutional standard of 176 
care defined at randomisation. All patients were followed up for a minimum of 24 177 
months at three monthly intervals comprising of physical examination, cystoscopy 178 
and urine cytology.  179 
2.5 Outcomes 180 
Co-primary outcome measures were disease-free survival time (DFS) for all patients 181 
and 3-month complete response (CR) for patients with biopsy-proven CIS at 182 
randomisation. DFS was determined as time from randomisation to earliest detection 183 
of histologically confirmed recurrence, positive urinary cytology or death. Three-184 
month CR for patients with CIS was defined as absence of visible tumour at 185 
cystoscopy, negative urinary cytology and no CIS on random bladder biopsy.  186 
Secondary outcome measures include: progression-free survival time (PFS), overall 187 
survival time (OS) and disease-specific survival time (DSS) in all patients; 188 
recurrence-free survival time (RFS) in non-CIS patients and safety and tolerability of 189 
RITE. Adverse events were recorded according to the NCI Common Toxicity Criteria 190 
of Adverse Events v4.0. Health related quality of life (HRQoL) was assessed at trial 191 
entry and three months intervals for 12 months using EQ-5D [16].  192 
2.6 Statistical analyses 193 
Statistical analyses were based on intention-to-treat (ITT). PPA was defined as 194 
patients receiving ≥6 treatments. Kaplan-Meier method was used to assess time-to-195 
event outcomes. As the primary analysis, treatment arms were compared using log-196 
rank test with a univariable Cox regression model used to determine unadjusted 197 
hazard ratios (HR). Secondary analysis used multivariable Cox regression model 198 
with stratification factors (CIS status and therapy history) included as covariates to 199 
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give adjusted HRs and p-values as a sensitivity analysis. Pre-specified subgroup 200 
analysis was used to assess treatment effects separately within each stratification 201 
factor and they were compared using a treatment-subgroup interaction term 202 
alongside their individual terms in a multivariable Cox regression model. CR rates 203 
are compared using an odds ratio (OR) and Fishers Exact test for patients with CIS 204 
at randomisation.  205 
The original sample size calculations anticipated that 242 patients with 81 events per 206 
arm would be required to detect an increase in DFS at 24 months from 45% to 60% 207 
(HR of 0.64) and in an embedded subgroup analysis of CIS patients, at least 27 208 
patients per arm would be required to detect an increase in three-month CR from 209 
40% to 80% (both 80% power,5% two-sided significance). Statistical analysis was 210 
performed using Stata v14. Statistical significance was considered when p<0.05. The 211 
study conferred to CONSORT guidelines.  212 
 213 
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3. RESULTS 225 
3.1 Patients 226 
The HYMN trial closed prematurely on February 2014 following a joint decision by 227 
the independent DMC and trial steering committee (TSC) due to a higher than 228 
expected CIS recurrence in RITE treated patients. A total of 104 patients (48 RITE 229 
vs 56 control) were randomised between May 2010 and July 2013 (Figure 1). Follow-230 
up ended on July 2017. 231 
Baseline patient characteristics were well balanced across treatment arms (Table 1). 232 
There was a higher proportion of papillary disease with concurrent CIS randomised 233 
to RITE compared to control (25% vs 18%, p=0.38). There was no difference in 234 
patients who had random biopsies at 3 months between treatment arms. At trial 235 
conception, it was estimated that 22% of patients would have CIS at baseline. 236 
However, the actual proportion was 68% (n=71). High risk NMIBC was defined in 237 
83% and 89% of the RITE and control arm respectively.  238 
3.2 Efficacy 239 
Disease-free survival analysis includes 73 events; 42 patients developed disease 240 
recurrence, 15 had recurrent CIS, 5 had disease progression and 11 patients died. 241 
Median follow-up time for the 31 patients without any of these DFS events was 36 242 
months with only 4 patients less than 24 months follow-up. No significant overall 243 
benefit was observed in DFS when comparing RITE to control (Figure 2a) with 24-244 
month DFS rate 35% versus 41% respectively (HR 1.33 [95% CI 0.84-2.10], p=0.23) 245 
(adjusted p=0.49). In the pre-planned co-primary analysis, there was no significant 246 
difference in the complete response rate of CIS at 3 months between RITE and 247 
control arms (30% vs 47%, OR 0.43 [95% CI 0.18-1.28], p=0.15). Pre-planned 248 
subgroup analysis showed that DFS of RITE treated patients were significantly lower 249 
than control in patients with baseline CIS (HR 2.06 [95% CI 1.17-3.62], p=0.01; 250 
Figure 2b). There was a non-significant higher DFS favouring RITE compared to 251 
control in non-CIS patients at baseline (HR 0.50 [95% CI 0.22-1.17], p=0.11; Figure 252 
2c). This treatment-subgroup interaction was statistically significant (p=0.007, Figure 253 
3). DFS in non-CIS patients at 24-months for RITE and control patients were 53% 254 
and 24% respectively. 255 
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The results for PPA were similar to ITT (Supplementary Figure 1). Subgroup analysis 256 
of previous BCG showed no significant treatment-subgroup interaction (Figure 3). 257 
Exploratory analysis of the effect of RITE on patients with CIS at baseline showed 258 
that the detrimental effect on DFS was marked in those with concurrent papillary and 259 
CIS disease (n=22) compared to those with CIS only (n=49) (Figure 3). There was 260 
no evidence of a differential treatment effect in CIS only patients (HR 1.53 [95% CI 261 
0.77-3.05], p=0.22). No difference between RITE and control was observed in PFS 262 
(8 patients with progression, 24-month rates 83% vs 87%, p=0.16), OS (30 deaths, 263 
24-month rates 85% vs 90%, p=0.18), and RFS (27 patients with disease recurrence 264 
in the 55 with papillary disease, 24-month rates 23% vs 40%; p=0.98) but a 265 
borderline difference in DSS (24-month rates 89% vs 96%; p=0.04) (Supplementary 266 
Table 2).  267 
3.3 Safety 268 
41 RITE patients and 48 control patients were included in the PPA. Five RITE 269 
patients did not complete ≥6 instillations due to adverse events: skin rash, urinary 270 
urgency and nocturia, inability to catheterise (n=2), haematuria, and patient refusal of 271 
treatment while five control arm patients were excluded due to the following adverse 272 
events: urinary urgency (n=2), persistent dysuria, haematuria, and patient refusal of 273 
treatment. Two patients in the RITE arm did not receive treatment: patient choice 274 
(n=1) and ineligibility post-randomisation (n=1). Three patients in the control arm 275 
were not treated: patient choice (n=2) and significant incontinence (n=2) after 276 
randomisation.  277 
One or more adverse events occurred in 84 (81%) patients (42 RITE patients vs 42 278 
control patients). No difference in adverse events between each treatment modality 279 
was observed (Table 2). Most adverse events were grade 1-2. There were two grade 280 
4 toxicity in the control arm which was due to arthritis and the other BCG related 281 
sepsis resulting in death. No difference in health-related quality of life was observed 282 
between the two treatment arms although RITE patients rated their health status 283 
higher than controls at three, six and nine months follow-up (Figure 4). 284 
 285 
 286 
 287 
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 4. DISCUSSION 288 
The aim of the HYMN was to determine if RITE is superior to standard of care in 289 
patients with recurrence of NMIBC following BCG. HYMN was a pragmatic study and 290 
in the absence of standard of care for this patient cohort who refuse cystectomy, pre-291 
planned treatment plan for control was determined by the local institution. HYMN 292 
remains the only RCT to test a novel therapy in this patient cohort. The trial showed 293 
no difference in DFS between RITE and standard therapy in all patients and three-294 
month CR rate in CIS patients at baseline. Pre-planned subgroup analysis of DFS 295 
showed RITE was beneficial in non-CIS patients (RITE 53% vs control 24% at 24-296 
months) although this was not statistically significant.  297 
A post-hoc analysis shows a higher number of concurrent papillary and CIS tumours 298 
in the RITE arm compared to control (25% versus 18%, p=0.38). The presence of 299 
CIS with papillary disease is associated with an increased risk of disease recurrence 300 
and progression and genomic studies suggest that these patients are genotypically 301 
similar to MIBC [17, 18]. It is plausible that patients with concurrent papillary and CIS 302 
have a significant risk of disease progression regardless of treatment modality.  303 
The rationale for hyperthermia follows in vitro and clinical studies which showed that 304 
increase in chemotherapy temperature can promote tissue permeation, promoting 305 
better drug absorption and synergistically increased tumour cell apoptosis [9]. 306 
Previous RCT data suggest a benefit for RITE compared to BCG or MMC in BCG 307 
naïve patients [11, 19]. In HYMN, we report that RITE treated non-CIS NMIBC 308 
patients had a lower DFS compared to control although  this was not significant. In a 309 
predominantly non-CIS cohort (1.2% CIS), Colombo et al. reported that RITE had a 310 
higher 24-month RFS compared to MMC alone (83% vs 43%, p<0.001)  and a 311 
durable response at 10-year RFS (53% vs 15%, p<0.001) [19, 20].  312 
Arends et al. randomised 190 patients to either RITE or BCG, both with maintenance 313 
therapy [11]. The proportion of patients with high risk disease was 31% (57/184) and 314 
23% (42/184) of patients had CIS at randomisation.  In ITT analysis, Arends et al. 315 
reported a higher but non-significant 24-month RFS favouring the RITE compared to 316 
BCG (78% vs 65%, p=0.08) in non-CIS disease. A PPA showed a significant benefit 317 
favouring RITE compared to BCG (81% vs 65%, p=0.02) however outcome for  CIS 318 
patients were not reported [11]. The non-CIS RITE treated patients in HYMN hints 319 
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towards similar results although there were only 33 patients in this pre-planned 320 
subgroup analysis.  321 
An important finding in HYMN is the efficacy of the control arm. A single arm study of 322 
Valrubicin in 90 cases of BCG-refractory CIS reported a 90-day CR rate of 21% 323 
which was sufficient evidence for FDA approval [21]. A Food and Drug 324 
Administration (FDA) public workshop and the International Bladder Cancer Group 325 
(IBCG) recommended that a single arm study design is sufficient to provide evidence 326 
of efficacy in the setting of recurrence following BCG therapy [22, 23]. Both the FDA-327 
AUA workshop and IBCG felt that a six-month CR rate of 40-50% and a RFS of ≥25-328 
30% at 18-24 months in BCG refractory-CIS would be clinically meaningful [22, 23]. 329 
Both RITE and control arm in HYMN achieved a 24-month DFS of 35% and 41% 330 
respectively, which was better than Valrubicin and above the recommended 331 
threshold for clinically meaningful effect although patients in HYMN would have a 332 
better prognosis as BCG relapsing and intolerant patients were included. We would 333 
caution that a control arm remains important for the design of studies to assess 334 
efficacy of novel agents in the setting of BCG failure NMIBC.  335 
Study limitations include that HYMN closed early at interim analysis and did not 336 
reach its recruitment target. Patients treated with RITE had 40 mg MMC which was 337 
consistent with the dosage used in two previous RCTs [11, 19]. A single arm study of 338 
RITE with 80mg MMC to treat CIS report a DFS of 86% with a mean follow-up of 26 339 
months suggest that a higher MMC dose might be more effective [24]. Up to 23% of 340 
patients in the control group received EMDA MMC which may be more effective than 341 
challenging to BCG although efficacy between these two treatments are similar in 342 
the randomised trial [25]. HYMN recruited a heterogenous group of BCG refectory, 343 
resistance and intolerance as this trial commenced before the FDA-AUA 344 
recommendations [23].  345 
 346 
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5. CONCLUSIONS 351 
DFS was similar between RITE and control treated patients. HYMN suggest the 352 
potential for RITE as a second line therapy for non-CIS recurrence following BCG 353 
although confirmatory trials are needed. RITE treated patients with CIS with/without 354 
papillary had lower DFS compared to control. RITE is well tolerated compared to 355 
control. HYMN highlights the importance of the control arm when evaluating novel 356 
therapies. 357 
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Figure 1: CONSORT diagram for the HYMN trial 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
HYMN primary analysis prepared for European Urology  
Figure 2: Kaplan-Meier curves for disease-free survival time: (A) all randomised 443 
patients (n=104) [HR: 1.33, 95% CI: 0.84-2.10, p=0.23]; (B) Pre-planned subgroup 444 
analysis of all randomised patients with CIS at baseline (n=71) [HR:2.06, 95% CI: 445 
1.17-3.62, p=0.01]; (C) pre-planned subgroup analysis of all randomised patients 446 
without CIS at baseline (n=33) [HR: 0.50, 95% CI: 0.22-1.17, p=0.11]. 447 
 448 
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Figure 3: Forest plot showing hazard ratios and 95% confidence intervals for disease-free survival time for pre-planned subgroup 471 
analysis of stratification factors (CIS status and previous BCG) and extended exploratory analysis of CIS status  472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
HYMN primary analysis prepared for European Urology  
20 
 
Figure 4: Mean EQ-5D score for RITE and control at baseline, 3, 6, 9 and 12 months 487 
 488 
   489 
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Table 1. Baseline characteristics of patients randomised 490 
Characteristic RITE  
(n=48) 
Control 
 (n=56) 
Sex: 
Male 
 
34 (71%) 
 
44 (79%) 
Age: Median (IQR) 77 (72-82) 76 (67-81) 
Smoking status: 
Never 
Previous 
Current 
 
15 (31%) 
28 (58%) 
5 (10%) 
 
16 (29%) 
39 (70%) 
1 (1.8%) 
Histology*: 
Papillary only 
Ta G2 
Ta G3 
T1 G2 
T1 G3 
Papillary and CIS 
Ta G1 
Ta G2 
Ta G3 
T1 G3 
CIS Only 
 
15 (31%) 
5 
6 
1 
3 
12 (25%) 
0 
3 
7 
2 
21 (44%) 
 
18 (32%) 
5 
5 
1 
7 
10 (18%) 
1 
0 
3 
6 
28 (50%) 
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Previous BCG*: 
Induction only (≤6 instillations 
Induction plus maintenance (>6 
instillations) 
 
18 (38%) 
30 (63%) 
 
19 (34%) 
37 (66%) 
Institutional Standard: 
BCG alone 
MMC alone 
EMDA MMC 
 
 
 
 
33 (59%) 
10 (18%) 
13 (23%) 
* CIS status (present or absent) and previous BCG therapy (induction only or 491 
induction plus maintenance) used as stratification variables at randomisation 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
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 Table 2: Reported adverse events stratified by treatment.  508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
  All grades Grades 3/4 
  RITE 
N=48 
Control 
N=56 
RITE 
N=48 
Control 
N=56 
Pain  46%  56% 4% 0% 
Dysuria 54%  59% 0% 0% 
Increased frequency  52% 54% 0% 2% 
Increased urgency  42% 48% 0% 4% 
Incontinence 23%  18% 0% 0% 
Nocturia  33%  38% 0%  4% 
Haematuria 48%  36% 2%  0% 
Fatigue  33%  38% 4% 2% 
Fever  13%  25% 0% 0% 
UTI  27%  18% 0% 2% 
Rash 15 % 25% 2% 4% 
Stricture 6% 4% 0% 0% 
HYMN primary analysis prepared for European Urology  
24 
 
References 517 
[1] Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms 518 
and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in 519 
Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of 520 
Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69:60-9. 521 
[2] Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non–522 
Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016. 523 
[3] Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines 524 
Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016;14:1213-24. 525 
[4] Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder 526 
cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer 527 
Treat Rev. 2016;47:22-31. 528 
[5] Tan WS, Lamb BW, Tan M-Y, Ahmad I, Sridhar A, Nathan S, et al. In-depth Critical Analysis of 529 
Complications Following Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion. 530 
Eur Urol Focus. 2016. 531 
[6] Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, et al. Early and late 532 
perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality 533 
in a contemporary series. J Urol. 2010;184:1296-300. 534 
[7] Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long-term followup of patients treated 535 
with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of 536 
response free of tumor. J Urol. 1990;144:652-7. 537 
[8] Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, et al. A randomized trial 538 
of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the 539 
bladder. J Urol. 2007;178:807-13. 540 
[9] van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA. EFFECT OF HYPERTHERMIA 541 
ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT 542 
OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. The Journal of urology. 543 
2005;173:1375-80. 544 
[10] Ware MJ, Tinger S, Colbert KL, Corr SJ, Rees P, Koshkina N, et al. Radiofrequency treatment 545 
alters cancer cell phenotype. Scientific reports. 2015;5:12083. 546 
[11] Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a 547 
Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus 548 
Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate-and High-risk Non–549 
Muscle-invasive Bladder Cancer. Eur Urol. 2016;69:1046-52. 550 
[12] Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined 551 
regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-552 
invasive bladder cancer: a systematic review. Eur Urol. 2011;60:81-93. 553 
[13] Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local 554 
bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. 555 
A preliminary clinical study. Eur Urol. 1991;20:204-10. 556 
[14] Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P. A new approach using local 557 
combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma 558 
treatment. J Urol. 1995;153:959-63. 559 
[15] van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European 560 
results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk 561 
superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46:65-71. 562 
[16] Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 563 
2001;33:337-43. 564 
[17] Park J, Song C, Hong JH, Park BH, Cho YM, Kim CS, et al. Prognostic significance of non-papillary 565 
tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 566 
bladder cancer. World J Urol. 2009;27:277-83. 567 
HYMN primary analysis prepared for European Urology  
25 
 
[18] Dyrskjøt L, Thykjaer T, Kruhøffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying 568 
distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33:90-6. 569 
[19] Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a 570 
randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant 571 
treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107:912-8. 572 
[20] Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing 573 
intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of 574 
recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270-6. 575 
[21] Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of 576 
valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. 577 
The Valrubicin Study Group. J Urol. 2000;163:761-7. 578 
[22] Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, et al. Clinical trial design for the 579 
development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug 580 
Administration and American Urological Association public workshop. Urology. 2014;83:262-4. 581 
[23] Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, et al. Definitions, End Points, and 582 
Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the 583 
International Bladder Cancer Group. J Clin Oncol. 2016;34:1935-44. 584 
[24] Lüdecke G, Schäfer L, Weidner W, Schmidt M, Hanitzsch H, Hasner F. Radiofrequency 585 
hyperthermia chemotherapy (HTC) in high- and extreme high-risk non-muscle-invasive bladder 586 
cancer (NMIBC) performed by the german HTC study group: impressive high chance of organ 587 
preservation documented in a cohort study with long-time follow-up. J Urol.189:e700. 588 
[25] Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical 589 
electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder 590 
cancer: a prospective randomized study. J Urol. 2003;170:777-82. 591 
 592 
